Evaluation of the efficacy of a new paracetamol formulation for buccal use after a single dose in patients with a moderate pain after a wisdom tooth extraction.
- Conditions
- Symptomatic short-term treatment of moderate painMedDRA version: 20.0Level: LLTClassification code 10036286Term: Post-operative painSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10059723Term: Tooth painSystem Organ Class: 100000004856Therapeutic area: Body processes [G] - Physiological processes [G07]
- Registration Number
- EUCTR2020-002220-37-IT
- Lead Sponsor
- ITHER PHARMACEUTICALS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 404
1. Male and female patient aged from 18 years of age at the time of signing the informed consent;
2. Patient scheduled to undergo the removal of one third soft-tissue impacted or not-impacted mandibular molar (associated or not to an ipsilateral erupted maxillary molar) under short-acting local anaesthetic (e.g., mepivacaine or lidocaine) preoperatively;
3. Patient weighing > 50 kg;
4. Female patient of childbearing potential must be willing to use a highly efficient birth control method during the study;
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
The following are considered as highly effective birth control methods:
Established use of oral, intravaginal or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation - Established use of oral, injected, or implanted progestogen-only hormonal contraception associated with inhibition of ovulation – Intrauterine hormone-releasing system or placement of an intrauterine device – Bilateral tubal occlusion – Vasectomised partner - True abstinence [periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception].
5. Patient able to understand and comply with protocol requirements and instructions;
6. Patient covered by national healthcare insurance system or similar system, if applicable by local regulations;
7. Patient who has signed a written informed consent obtained prior to any study-related procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 4
1. Patient who undergoes an extraction of contralateral molar in the same procedure or a bony-impacted molar;
2. Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) within the 3 days prior to the day of randomization (or within 5 times the elimination half-life whichever the longest);
3. Patient who received other analgesic than short-acting preoperative or intraoperative local anaesthetic agents within 12 hours before the start of the surgery or peri-operatively until randomization;
4. Patient with any known hypersensitivity to paracetamol, ibuprofen or ingredients contained in Investigational Medicinal Products (IMP) and Non-Investigational Medicinal Products (NIMP);
5. Patient with contra-indication to the alcoholic solution for medical reason (alcoholic weaning or abuse, epilepsy);
6. Women with positive results on a urine pregnancy test or breastfeeding women or women of childbearing potential without an effective contraception;
7. Patient with current or chronic history of liver disease, or known hepatic or biliary abnormalities;
8. Patient with a current or chronic history of severe renal impairment;
9. Patient with severe heart failure (New York Heart Association (NYHA) Class IV);
10. Patient with history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
11. Patient with gastrointestinal haemorrhage, cerebrovascular haemorrhage or of other evolving haemorrhage;
12. Patient with an active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding);
13. Patient with inflammation or ulcerative disease of the oral mucosa (i.e., aphthae…);
14. Patient with known systemic lupus erythematosus;
15. Patient having developed hypersensitivity reactions, including symptoms of asthma, rhinitis, angioedema or urticaria after taking acetylsalicylic acid or other NSAIDs;
16. Patient with drug or alcohol abuse within 6 months before dosing with study medication; Alcohol abuse is defined as the consumption of more than 90 mL of liquor or spirits or 530 mL of beer per day, for 5 consecutive days during the 6-month period. Drug abuse is defined as the use of any recreational drug for 5 consecutive days during the 6-month period.
17. Patient having participated in any clinical research study within the previous 30 days or 5 half-lives duration of the biological effect of the investigational product (whichever is longer);
18. Patient having any current dental or medical condition that could prevent safe participation in this study;
19. Unwillingness or inability to follow the procedures outlined in the protocol.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method